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that (i.e., retreatment); 3) Annualized resource use stratiﬁed by
retreatment status. RESULTS: Of the 45 patients who met study
inclusion criteria, mean age was 61.8 and 62.2% were male.
46.7% of patients (n = 21) had medication use >1 month after
the recommended treatment regimen. 73.3% (n = 33) had a gap
in treatment, and of these, 24.2% (n = 8) were retreated after
the gap. Annualized resource utilization (mean (SD)) for not
retreated vs. retreated patients respectively was: Physician visits:
2.0 (2.0) vs. 4.2 (3.9), p = 0.16; Specialist visits: 1.0 (2.1) vs. 2.7
(2.9), p = 0.16; SAP tests: 0.3 (0.8) vs. 0.8 (2.8), p = 0.32; and
Bisphosphonate prescriptions: 1.7 (2.3) vs. 4.2 (3.9), p = 0.12.
CONCLUSIONS: This analysis of real-world treatment patterns
and resource use in risedronate-treated patients suggests a large
extent of risedronate use beyond approved label recommenda-
tions and high retreatment rates, as well as higher resource use
in those retreated. Larger studies are warranted to further under-
stand treatment patterns and associated resource utilization in
Paget’s disease patients.
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OBJECTIVES: Cost-effectiveness analyses are routinely based on
data from group averages, restricting its generalizibility to those
with below- or above-average risk. A pharmaco-economic model
was developed that used individualised risks, taking as example
bisphosphonates and prevention of fractures. METHODS: Data
were obtained from a research database of general practitioners,
comprising a sample of the UK general population of women 
>50 years (N = 330,000). Individual mortality and hip, verte-
bral, and other osteoporotic fracture risks were estimated by age,
sex, body mass index, smoking and other clinical risk factors.
Estimates on costs, EQ5D utilities and treatment efﬁcacy were
obtained from a UK national report (NICE) and outcomes were
simulated over a ten-year period. RESULTS: There was a large
variability in the cost-effectiveness with clinical risk factors. At
age 60–69, the cost per QALY gained was ≤136k in women with
low fracture risk but ≤36k with high fracture risk (data for
women without fracture history). Patients with low body mass
index (<20) had considerable better cost-effectiveness than
patients with high BMI (≥26) (≤23k versus ≤71k at age 60–79
in women without fracture history). The same was found for dif-
ferent diseases such as rheumatoid arthritis or inﬂammatory
bowel disease. Using a cost-acceptability ratio of ≤30k per
QALY gained, bisphosphonates became cost-effective for
patients with a ﬁve-year risk of 9.3% (95% CI 8.0–10.5%) for
osteoporotic fractures and of 2.1% (95% CI 1.5–2.7%) for hip
fractures. Including bone mineral density in the risk assessment,
the cost per QALY gained was ≤35k in women at age 60 with
a fracture history and a T-score of -2.5 (at age 80, this was 
≤3k). CONCLUSIONS: A pharmaco-economic model based on
individual long-term risks (as derived from a health care data-
base) can improve the targeting in a cost-effective manner of
therapy to patients.
OSTEOPOROSIS—Patient Reported Outcomes
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OBJECTIVES: To assess patient adherence with bisphospho-
nates at 6 months of therapy utilizing an integrated administra-
tive, medical and pharmacy claims database. METHODS: A
retrospective cohort study was conducted among 128,362
women, 45 years of age and older, with a new (index) prescrip-
tion for risedronate (35mg/week) or alendronate (35mg/week or
70mg/week) between May 1, 2002, and December 31, 2003. All
eligible patients were required to be continuously enrolled for
the six months preceding and the 12 months following the index
date and to have ﬁlled at least 2 continuous bisphosphonate pre-
scriptions, as deﬁned below. The six-month history was used to
assess baseline clinical characteristics, including fracture history,
gastrointestinal conditions, hospitalizations, and glucocorticoid
use. Adherence with therapy was then assessed for the ﬁrst 6
months of bisphosphonate treatment. Patient adherence was
deﬁned as continuous reﬁlling of the weekly bisphosphonate
treatment with no gaps exceeding 90 days during the follow-up
period. RESULTS: The average bisphosphonate user in this study
was aged 64 years; 78% initiated with alendronate and 22%
with risedronate. Almost 4% had a history of fragility fractures
(vertebral and/or non-vertebral) and 18% used oral glucocorti-
coids during the study period. At 6 months, 71% of bisphos-
phonate patients were adherent with therapy. An additional 22%
discontinued, and subsequently resumed treatment after a mean
treatment gap of 164 days. The following patient characteristics
were correlated with a higher likelihood of therapy discontinu-
ation: younger age, GI event after the index date, oral glucocor-
ticoid use, and history of GI events, hospitalization, or fracture.
CONCLUSIONS: This study demonstrates that seven in ten new
bisphosphonate users remained on therapy at six months after
treatment initiation. An additional two in ten patients resumed
therapy after a mean treatment gap of ﬁve months. Overall, the
majority of patients who initiated bisphosphonates were adher-
ent after the ﬁrst six months of treatment.
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OBJECTIVES: To determine the rates of compliance; discontin-
uation; and switching of treatment with bisphosphonates, calci-
tonin, estrogens, parathyroid hormones, and raloxifene in
Louisiana Medicaid post-menopausal women with diagnosis of
osteoporosis and/or fracture. METHODS: Medical and phar-
macy administrative claims data obtained from the Louisiana
Department of Health and Hospitals were used for the study.
The data contain paid claims for all Louisiana Medicaid recipi-
ents. Women age 50 and older diagnosed with osteoporosis
and/or a fracture between July 1, 2002 and June 30, 2003 and
continuously eligible 12 months prior through 24 months after
their initial diagnosis were included in the study. Women with
Medicare eligibility and those who received a prescription for
osteoporosis and/or fracture 12 months prior were excluded.
There were 1772 women who met the inclusion criteria. Claims
data on these women were studied for two years from the date
of their initial diagnosis. Women were considered compliant if
the difference between their ﬁll dates did not exceed 45 days.
Women were considered discontinuers if they ﬁlled prescriptions
only once in the two-year study period. Recipients were consid-
ered switchers if they switched from one drug to another, single
to combination therapy, or combination to single therapy.
RESULTS: Of the 1772 in the study group, 28% (500) received
treatment, and of those, 57% were on a single drug, 22% on
multiple drugs, and 21% discontinued treatment. The compli-
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ance rate was 67% for women receiving a single drug and 22%
for multiple drug treatment. The rate of switching was 89% in
non-compliant and 68% in the compliant groups. CONCLU-
SIONS: The rate of compliance was lower for women on 
multiple drugs compared to those on single drug therapy. Non-
compliant women are more likely to switch drug therapies than
the compliant women.
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OBJECTIVES: The objective of the study is to assess the feasi-
bility and acceptance of computer-mediated home-based reha-
bilitation of hip fracture patients. METHODS: A structured
exercise program was developed by a physical therapist (PT) and
incorporated into a website where the PT could prescribe,
monitor, and modify an individualized exercise plan. The
patients were given a laptop computer that was operated by a
limited number of keys. The computer guided the patients
through their exercise programs and sent daily exercise logs to
a central server which analyzed patient performance and alerted
the PT if certain clinical condition were met. Overall, ten patients
were enrolled in the study who were monitored for 30 days.
RESULTS: The average age of the subjects was 76 ± 9 years in
whom number of days since hip fracture was 159 ± 143. There
was a signiﬁcant improvement from the beginning to the end of
the study in exercise self-efﬁcacy (6 ± 3 vs. 9 ± 1; p = 0.01),
Lower Extremity Functional Scale (55 ± 16 vs. 63 ± 13; p = 0.03),
and quality of life scale (SF-36) including physical functioning
(38 ± 27 vs. 71 ± 31; p = 0.009), physical problems limitations
(6 ± 10 vs. 17 ± 12; p = 0.05), social functioning (54 ± 31 vs.
85 ± 28; p = 0.01) and health transition (47 ± 40 vs. 22 ± 18; p
= 0.05). Using Yale Physical Activity Survey we found improve-
ment in physical intensity measured as total hours/week (24 ±
14 vs. 31 ± 14; p = 0.04). Based on the Client Satisfaction Ques-
tionnaire (CSQ-8), patient satisfaction with their medical care
also improved (27 ± 4 vs. 31 ± 0.46; p = 0.04). Adherence to the
exercises was above 89%. CONCLUSION: Computer-mediated
home-based rehabilitation program could be beneﬁcial for post-
acute hip fracture recovery.
OTHER—Cost Studies
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OBJECTIVES: To examine the incidence and potential ﬁnancial
impact of diseases with associated hyponatremia among hospi-
talized patients in the United States. METHODS: A retrospec-
tive analysis of Medicare inpatient coding procedures, length of
stay (LOS) and Medicare hospital reimbursement data (2004) to
estimate direct costs of 176 private, for-proﬁt hospitals with
coding accuracy validated by Medicare review of patient dis-
charge charts. Data from one hospital were used to perform
detailed cost/reimbursement analyses. Relevant cases were iden-
tiﬁed by searching with the ICD-9-CM code for hyponatremia
(276.1) drilling down within all DRGs to quantify the incidence
of hyponatremia, associated ﬁnancial impact and costs hypona-
tremia may have. RESULTS: In the 176 hospitals, hyponatremia
was found as a secondary diagnosis or coexisting condition in
16,791 cases. Most common DRGs that included a diagnosis of
hyponatremia were congestive heart failure (CHF, n = 13,778),
syndrome of inappropriate secretion of antidiuretic hormone
(SIADH, n = 1355), and transurethral resection of the prostate
(TURP syndrome, n = 193). Hyponatremia was identiﬁed in
73% (7398/10,073) of complicated CHF cases and in 25%
(6380/25,038) of uncomplicated CHF cases. In a typical hospi-
tal with 190 uncomplicated CHF cases annually, the mean cost
of an uncomplicated CHF case was $6247, whereas the mean
reimbursement was $3667, suggesting a loss of $2580 per case
(annual loss of $490,200). If complicated CHF cases were con-
sidered, the typical hospital’s annual loss was estimated at
$2,883,096. Endocrine disorders including SIADH cost between
$12,305 and $24,745 and are reimbursed at $3,861. New ther-
apies providing predictable correction of serum sodium levels
may mitigate the economic impact of hyponatremia associated
with underlying conditions by reducing the length of stay (LOS),
physician attending time, or frequent laboratory studies. CON-
CLUSIONS: The incidence and economic impact of hypona-
tremia is high among patients with complicated CHF, TURP
syndrome, and SIADH. Improved treatment of hyponatremia
may help relieve this burden.
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FATIGUE IN THE U.S.WORKFORCE: PREVALENCE AND COST
OF LOST PRODUCTIVE WORK TIME
Ricci J, Chee E, Lorandeau A
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OBJECTIVE: To estimate the prevalence of fatigue and accom-
panying lost labor costs (work absence and reduced performance
while at work) among US workers. METHODS: Cross-sectional
study using data from the Caremark American Productivity
Audit, a national random-digit-dial telephone survey of the US
population designed to measure the relation between health and
work productivity. The sample comprised 28,902 employed
adults participating in the audit between August 1, 2001, and
July 30, 2002. A total of 11,719 workers with fatigue were iden-
tiﬁed. A comparison group consisted of a gender- and age-
matched random sample (1 :1) of workers without fatigue.
Outcome measures included fatigue prevalence, lost productive
time (LPT) due to fatigue and LPT for any health-related reason
expressed in hours and converted to dollars. RESULTS: The esti-
mated two-week period prevalence of fatigue in the U.S. work-
force was 37.9%. Overall, 9.2% of workers with fatigue
reported LPT due to fatigue in the previous two weeks. This
group lost 4.1 productive hours per week, on average, and cost
employers an estimated $330 million per year; 83.9% of the LPT
cost was due to reduced performance while at work. Compar-
ing LPT for any health-related reason between workers with and
without fatigue, workers with fatigue cost US employers an esti-
mated $136.4 billion per year in health-related LPT, an annual
excess of $101.0 billion. Excess health-related LPT is primarily
explained by the mean threefold increase in the percent of
workers reporting LPT due to other health conditions when
fatigue is present. CONCLUSIONS: Fatigue is prevalent in the
US workforce and can impair work ability. When present as a
secondary symptom to other health conditions, fatigue is asso-
ciated with signiﬁcantly more LPT due to those conditions.
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